A director at Abivax sold after exercising options/sold 1,104,640 shares at 54.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Eramet: Increased focus on operational efficiency following a highly pressured H1 2025 Paris, 30 July 2025, 6:30 p.m. PRESS RELEASE Eramet: Increased focus on operational efficiency following a highly pressured H1 2025 Safety performance remained strong in H1 2025, with a Group TRIFR1 of 0.6 Adjusted EBITDA (excluding SLN)2 at €191m, down 45% vs. H1 2024, primarily from the reduced contribution of PT WBN (-€92m, representing nearly 2/3 of the decline) attributable to: The planned start of new mining production sites at Weda Bay in Indonesia, compounded by constrained operating permit,...
Eramet : priorité à l’efficacité opérationnelle après un 1er semestre 2025 sous forte pression Paris, le 30 juillet 2025, 18h30 COMMUNIQUE DE PRESSE Eramet : priorité à l’efficacité opérationnelle après un 1er semestre 2025 sous forte pression Solide performance en matière de sécurité au S1 2025, avec un TF21 Groupe de 0,6 EBITDA ajusté (hors SLN)2 à 191 M€ en baisse de 45 % par rapport au S1 2024, principalement en raison de la contribution réduite de PT WBN (- 92 M€, soit près de 2/3 de la baisse) s’expliquant par : Le démarrage prévu de nouveaux sites de production minière à Weda B...
We are significantly raising our TP from € 24 to € 88 following the positive results of the phase 3 induction trial (ABTECT) for obefazimod in ulcerative colitis. Obefazimod achieved significant clinical remission rates higher than those observed in phase 2b, and comparable to the best agents under development. Based on these results, we believe that Abivax is a credible M&A target for a pharma player looking to strengthen its position in immunology. Outperform rating reiterated.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.